Emerging Company in the Spotlight sponsored by JFK Communications.
BioNJ is pleased to shine the spotlight on one of our Innovation Members each month featuring their progress and work on behalf of Patients and their impact on the New Jersey life sciences ecosystem. This month’s Emerging Company in the Spotlight is Soligenix.
So many of our Members are making a dramatic impact on our State’s innovative ecosystem. We celebrate you!
Soligenix, Inc., headquartered in Princeton, N.J., is a late-stage biopharmaceutical company committed to developing and commercializing products that treat rare diseases where there is an unmet medical need. As a rapidly growing company, Soligenix supports a robust pipeline of innovative drug candidates through two business segments: a BioTherapeutics segment and a Vaccines/Biodefense segment.
Through the BioTherapeutics segment, Soligenix develops products for orphan diseases such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease and acute radiation enteritis. The pivotal Phase 3 clinical trial of SGX203 (oral beclomethasone dipropionate), for the treatment of pediatric Crohn’s disease, as well as the pivotal Phase 3 trial of SGX301 (synthetic hypericin), for cutaneous T-cell lymphoma, was announced earlier this year. The SGX301 trial recently initiated enrollment and the SGX203 trial is expected to initiate in the first half of 2016. Both have been granted orphan drug and fast track designations from the US Food and Drug Administration (FDA). In addition, positive preliminary results were recently reported in the Company’s Phase 2 proof-of-concept trial in oral mucositis with SGX942, a novel, first-in-class innate defense regulator (IDR) technology that modulates the body’s reaction to both injury and infection towards an anti-inflammatory and an anti-infective response. The Phase 2 preliminary results reported by Soligenix showed a significant reduction in the duration of severe oral mucositis in patients receiving chemoradiation therapy for treatment of their head and neck cancer.
Through the Vaccines/Biodefense business segment, Soligenix develops vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome and melioidosis. In partnership with the University of Colorado, Soligenix has also developed ThermoVax®, a proprietary heat stabilization technology. The ThermoVax® technology, in which a liquid vaccine can be dried out to a powder and stored at elevated temperatures, has the potential to facilitate easier storage and distribution of strategic national stockpile vaccines in emergency settings. The Biodefense segment is supported with up to $57 million in government grant and contract funding from the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
“We have a robust and diversified pipeline with late-stage assets that aim to rise to the challenge of rare disease treatment and biodefense,” said Dr. Christopher J. Schaber, President and Chief Executive Officer of Soligenix, Inc. and Member of the Board of BioNJ. “We additionally have multiple near-term potential value drivers over the next 12 to 24 months that will build significant value for investors. Just as important, we have an experienced and dedicated team at Soligenix that is committed to aggressively moving this important pipeline forward to potential success.”
Soligenix is seeking to identify new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of gastrointestinal, supportive cancer care and biodefense. For those interested in exploring business opportunities, please contact Joseph Warusz, CPA, MBA, Acting Chief Financial Officer, Soligenix, at email@example.com. For more information on Soligenix, Inc., visit www.soligenix.com.